NCT06898307 Utility of Gene Test Analysis for Diagnosis, Prognosis and Treatment of Patients With Genetic Arrhythmic Heart Disease: the ARRHYTHMIC GENE-HEART
| NCT ID | NCT06898307 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital of Ferrara |
| Condition | Genetic Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2017-11-01 |
| Primary Completion | 2025-11-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2017-11-01 with a primary completion date of 2025-11-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to enroll all patients evaluated at the specialized Cardiogenetic Center within the Cardiology Department of the University of Ferrara, Italy. The primary aim of the registry is to collect comprehensive clinical, genetic, and electrophysiological data from individuals with suspected or confirmed arrhythmogenic conditions. By systematically documenting patient demographics, family history, clinical presentations, diagnostic findings, and treatment outcomes, the registry seeks to enhance our understanding of the genetic basis and clinical implications of genetically driven arrhythmias and systemic syndromes. This registry will facilitate long-term follow-up of enrolled patients to assess the natural history of arrhythmogenic disorders and the effectiveness of various therapeutic interventions. Additionally, it aims to identify potential risk factors associated with adverse outcomes, such as sudden cardiac death or major arrhythmic events.
Eligibility Criteria
Inclusion Criteria: * Patients evaluated at the Cardiogenetic Center of the University of Ferrara in Ferrara, Italy. * Having a proven cardiogenetic disease Exclusion Criteria: * Refuse to provide informed consents * Patients not having a cardiogenic disease
Contact & Investigator
Cristina Balla, MD PhD
PRINCIPAL INVESTIGATOR
Università degli Studi di Ferrara
Frequently Asked Questions
Who can join the NCT06898307 clinical trial?
This trial is open to participants of all sexes, studying Genetic Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06898307 currently recruiting?
Yes, NCT06898307 is actively recruiting participants. Contact the research team at bllcst@unife.it for enrollment information.
Where is the NCT06898307 trial being conducted?
This trial is being conducted at Ferrara, Italy.
Who is sponsoring the NCT06898307 clinical trial?
NCT06898307 is sponsored by University Hospital of Ferrara. The principal investigator is Cristina Balla, MD PhD at Università degli Studi di Ferrara. The trial plans to enroll 200 participants.